Exploiting SR-B1 for the development of new immunomodulatory drugs to enhance cancer immunotherapy
- Convocation: Health R&D Projects. AES 2016
- Reference: PI16/00668
- Duration: 3 years
- Start date: January 1, 2017
- End date: December 31, 2019
- Funder: Instituto de Salud Carlos III y cofinanciado por el Fondo Europeo de Desarrollo Regional (FEDER) “Una manera de hacer Europa”
- Nature of project: National
Need more information?
If you are interested in learning more about our research, please contact us.